Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnin : vimarsana.com

Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived Interleukin 12 in healthy volunteersAnnounced early safety data from the company's Phase 1b/2a clinical trial of SON-080 in patients with chemotherapy-induced peripheral neuropathy (CIPN)Rece...

Related Keywords

India , Australia , New Jersey , United States , American , Pankaj Mohan , Jack Yauch , Jay Cross , Securities Exchange , Sonnet Biotherapeutics Inc , Exchange Commission , Solebury Strategic Communications , Jersey Technology Business Tax Certificate Transfer Program , American Association For Cancer Research , Sonnet Biotherapeutics Holdings Inc , Nasdaq , Published Phase , American Association , Cancer Research , Sonnet Founder , Chief Executive , Recent Corporate , Data Safety Monitoring Board , Diabetic Peripheral Neuropathy , Dose Interleukin , Quarter Ended March , Fully Human Albumin Binding , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Months Ended March ,